Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

NCT00538915 | Completed Phase 3 Results

• 1 other identifier: Nabi-7101
• Study Type: interventional
• Target: 63
• Locations: 1 country
• Sites: 17

Brief Summary

The purpose of this study is to determine if NABI-IGIV (10%) \[Immune Globulin Intravenous (Human), 10%\] is safe and effective in preventing serious bacterial infections (SBIs) in the treatment of patients with primary immune deficiency disorders (PIDD) when compared to historical control data.

Conditions

Primary Immune Deficiency Disorders (PIDD)

Keywords

immunodeficiency; humoral immunity; antibody deficiency; PID; PIDD

Outcome Measures

Primary Outcomes (1)

• Rate of Serious Bacterial Infections (SBIs) Per Person-year on Treatment

  Serious bacterial infections (SBIs) rate per person-years, including bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia and visceral abscess.

  One year

Study Arms (1)

Nabi-IGIV Infused Every 3- or 4-Weeks

EXPERIMENTAL

Biological: Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]

Interventions

Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%] BIOLOGICAL

Nabi-IGIV 10% \[Immune Globulin Intravenous (Human), 10%\] is a clear or slightly opalescent, colorless to pale yellow sterile solution of 10% protein concentration of immunoglobulin G (100mg/mL). It is packaged as 5g in 50mL solution and 10g in 100mL solution. Dosing will be 300-800 mg/kg based on subject's prior dosing history. Infusions will be every 3 or 4 weeks.

Nabi-IGIV Infused Every 3- or 4-Weeks

Eligibility Criteria

• Age: 6 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female, age ≥ 6 and ≤ 75, with a documented and confirmed pre-existing diagnosis of chronic primary immune deficiency (PIDD) with a low total immunoglobulin G (IgG) level and deficient antibody production before chronic therapy (i.e., X-linked agammaglobulinemia, common variable immunodeficiency (CVID), Hyper IgM Syndrome with immunoglobulin G (IgG) deficiency, etc).
• Currently on immune globulin intravenous (IGIV) replacement therapy at a fixed interval and dosage with a total monthly dose of immune globulin intravenous (IGIV) between 300 and 800 mg/kg that has been stable for at least 3 months prior to screening.
• Documented (within 3 months) plasma immunoglobulin G (IgG) trough level of \>500 mg/dL on current immunoglobulin G (IgG) therapy \[immunoglobulin G (IgG) levels may be obtained at screening if previous results not available\].
• Medical records documenting infections and treatment within the previous 2 years need to be available for review.
• Subject or legal guardian(s) must have given written informed consent/assent.
• If a menstruating female, have a negative serum or urine pregnancy test within 7 days prior to the first dose of Nabi-IGIV \[immune globulin intravenous (Human) 10%\] and agree to use an acceptable method of contraception or be at least one year post-menopausal or surgically sterile.

You may not qualify if:

• Received any blood product \[other than immune globulin intravenous (IGIV)\] within the last 3 months prior to screening or received any investigational agent \[other than immune globulin intravenous (IGIV)\] within the last four weeks prior to receiving Nabi-IGIV \[immune globulin intravenous (Human) 10%\].
• Known history of medically significant adverse reactions to other immunoglobulin G (IgG) or blood products.
• Known selective immunoglobulin A (IgA) deficiency, history of allergic reaction to products containing immunoglobulin A (IgA) or has a history of antibodies to immunoglobulin A (IgA).
• Known significant proteinuria and/or has a history of acute renal failure/or severe renal impairment \[blood urea nitrogen (BUN) or creatinine more than 1.5 times the upper limit of normal\].
• Known history or current diagnosis of deep venous thrombosis.
• Known medical condition that is known to cause secondary immune deficiency, such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, human immunodeficiency virus (HIV) infection, acquired immunodeficiency syndrome (AIDS), or chronic or recurrent neutropenia (absolute neutrophil count less than 500 mm3).
• Current daily use of corticosteroids (\> 10 mg of prednisone equivalent /day for \> 30 days), immunosuppressants or immunomodulators. (Intermittent corticosteroid use during the study is allowable, if medically necessary.)
• Known non-controllable arterial hypertension (systolic blood pressure (BP) \> 160 mmHg and /or diastolic BP \>100 mmHg.)
• Known anemia at screening (hemoglobin \<10 g/dL).
• Subject is pregnant or lactating.
• Known history of illicit drug use within 3 months prior to the administration of the investigational product and for the study duration.
• Have any condition judged by the study physician to preclude participation in the study, including any psychological disorder, which might hinder compliance.
• Known active viral or bacterial infection or symptoms/signs consistent with such an infection within the two weeks prior to the initial dose of investigational product infusion. Subjects may be on antibiotics as long as signs/symptoms of infection have been absent for two weeks prior to the initial infusion of investigational product (IP).
• Expectation of non-compliance with the protocol procedures and visit schedule.

Sponsors & Collaborators

• ADMA Biologics, Inc.: lead

Study Sites (17)

University of Alabama

Birmingham, Alabama, 35294, United States

Location

Precision Trials LLC

Phoenix, Arizona, 85032, United States

Location

Children's Hospital of Los Angeles

Los Angeles, California, 90027, United States

Location

1st Allergy and Clinical Resaerch center

Centennial, Colorado, 80112, United States

Location

Allergy Associates of the Palm Beaches

North Palm Beach, Florida, 33408, United States

Location

Marietta Pulmonary Medicine

Marietta, Georgia, 30060, United States

Location

Rush University Medical center

Chicago, Illinois, 60612, United States

Location

South Bend Clinic LLP

South Bend, Indiana, 46617, United States

Location

Kentuky Lung Clinic, PSC

Hazard, Kentucky, 41701, United States

Location

Institute For Allergy & Asthma

Wheaton, Maryland, 20902, United States

Location

Cardinal Glennon Children's MC

St Louis, Missouri, 63104, United States

Location

Women's and Children's Hospital of Buffalo

Buffalo, New York, 14222, United States

Location

University Hospital Case medical center

Cleveland, Ohio, 44103, United States

Location

Allergy/Immunology Research Center of north Texas

Dallas, Texas, 75230, United States

Location

AARA Research

Dallas, Texas, 75231, United States

Location

Allergy, Asthma & Immunology Clinic, PA

Irving, Texas, 75063, United States

Location

Bellingham Asthma, Allergy Clinic

Bellingham, Washington, 98225, United States

Location

MeSH Terms

Conditions

Primary Immunodeficiency Diseases; Immunologic Deficiency Syndromes

Interventions

gamma-Globulins

Condition Hierarchy (Ancestors)

Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Immune System Diseases

Intervention Hierarchy (Ancestors)

Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Results Point of Contact

• Title: Richard L. Wasserman, M.D., Ph.D.
• Organization: DallasAllergyImmunology

drrichwasserman@gmail.com

(972) 566-7788

Study Officials

• Shailesh Chavan, M.D.

  Biotest Pharmaceuticals Corporation

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: LTE60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 1, 2007
• First Posted: October 3, 2007
• Study Start: September 1, 2007
• Primary Completion: July 1, 2009
• Study Completion: July 1, 2009
• Last Updated: July 30, 2021
• Results First Posted: March 26, 2012

Record last verified: 2012-02

Locations

US (17)